Table of Contents Author Guidelines Submit a Manuscript
Radiology Research and Practice
Volume 2014, Article ID 135934, 12 pages
http://dx.doi.org/10.1155/2014/135934
Clinical Study

18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Accuracy in the Staging of Non-Small Cell Lung Cancer: Review and Cost-Effectiveness

1Department of Radiology, Research Institute La Princesa, La Princesa University Hospital, C/Diego de León 62, 28006 Madrid, Spain
2Health Technology Assessment Unit, Lain Entralgo Agency, C/Gran Vía 27, 28013 Madrid, Spain
3National School of Health, Sinesio Delgado 4, 28029 Madrid, Spain
4Institute for Health and Consumer Protection, Joint Research Centre, European Commission, Via E. Fermi 2749, 21027 Ispra, Italy

Received 11 June 2014; Revised 26 September 2014; Accepted 1 October 2014; Published 5 November 2014

Academic Editor: Paul Sijens

Copyright © 2014 Nieves Gómez León et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward et al., “Cancer statistics, 2008,” CA Cancer Journal for Clinicians, vol. 58, no. 2, pp. 71–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Yang, M. S. Allen, M. C. Aubry et al., “Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003,” Chest, vol. 128, no. 1, pp. 452–462, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. L. H. Sobin, M. K. Gospodarowicz, and C. Wittekind, “Lung (ICD-O C34),” in TNM Classification of Mali gnant Tumors, L. H. Sobin, M. K. Gospodarowicz, and C. Wittekind, Eds., pp. 138–146, Blackwell Publishing, Chichester, UK, 7th edition, 2010. View at Google Scholar
  4. B. A. Dwamena, S. S. Sonnad, J. O. Angobaldo, and R. L. Wahl, “Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—Meta-analytic comparison of PET and CT,” Radiology, vol. 213, no. 2, pp. 530–536, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. J. W. Fletcher, B. Djulbegovic, H. P. Soares et al., “Recommendations on the use of 18F-FDG PET in oncology,” Journal of Nuclear Medicine, vol. 49, no. 3, pp. 480–508, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Bradbury, E. Bonell, J. Boynton et al., “Positron emission tomography (PET) imaging in cancer management,” Health Technology Assessment Report 2, Health Technology Board for Scotland, Glasgow, Scotland, 2002. View at Google Scholar
  7. NICE and National Collaborating Centre for Acute Care, Diagnosis and Treatment of Lung Cancer, National Collaborating Centre for Acute Care, London, UK, 2005, http://www.rcseng.ac.uk/.
  8. Ministerio de Sanidad, Política Social e Igualdad. Pesos y costes de los GRDs del Sistema Nacional de Salud, http://www.msssi.gob.es/estadEstudios/estadisticas/inforRecopilaciones/anaDesarrolloGDR.htm.
  9. “ORDEN 629/2009, de 31 de agosto, por la que se fijan los precios públicos por la prestación de los servicios y actividades de naturaleza sanitaria de la red de centros de la Comunidad de Madrid,” Boletín Oficial de la Comunidad de Madrid, no. 215, 2009.
  10. S. F. Altekruse, C. L. Kosary, M. Krapcho et al., SEER Cancer Statistics Review, 1975–2007, National Cancer Institute, Bethesda, Md, USA, 2010, http://seer.cancer.gov/csr/1975_2007.
  11. S. S. Gambhir, C. K. Hoh, M. E. Phelps, I. Madar, and J. Maddahi, “Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma,” Journal of Nuclear Medicine, vol. 37, no. 9, pp. 1428–1436, 1996. View at Google Scholar
  12. B. Nafees, M. Stafford, S. Gavriel, S. Bhalla, and J. Watkins, “Health state utilities for non small cell lung cancer,” Health and Quality of Life Outcomes, vol. 6, article 84, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Asukai, A. Valladares, C. Camps et al., “Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: Results for the non-squamous histology population,” BMC Cancer, vol. 10, article 26, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. W. A. Weber, “Use of PET for monitoring cancer therapy and for predicting outcome,” Journal of Nuclear Medicine, vol. 46, no. 6, pp. 983–995, 2005. View at Google Scholar · View at Scopus
  15. S. J. Uybico, C. C. Wu, R. D. Suh, N. H. Le, K. Brown, and M. S. Krishnam, “Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls,” Radiographics, vol. 30, no. 5, pp. 1163–1181, 2010. View at Publisher · View at Google Scholar · View at Scopus
  16. P. J. Neumann, C.-H. Fang, and J. T. Cohen, “30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement,” PharmacoEconomics, vol. 27, no. 10, pp. 861–872, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. M. F. Drummond and T. O. Jefferson, “Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party,” The British Medical Journal, vol. 313, pp. 275–283, 1996. View at Google Scholar
  18. R. Goeree, B. J. O'Brien, and G. Blackhouse, “Principles of good modeling practice in healthcare cost-effectiveness studies,” Expert Review of Pharmacoeconomics and Outcomes Research, vol. 4, no. 2, pp. 189–198, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. J. R. Beck, S. G. Pauker, J. E. Gottlieb, K. Klein, and J. P. Kassirer, “A convenient approximation of life expectancy (The “DEALE”). II. Use in medical decision-making,” The American Journal of Medicine, vol. 73, no. 6, pp. 889–897, 1982. View at Publisher · View at Google Scholar · View at Scopus
  20. B. J. O'Brien and A. H. Briggs, “Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods,” Statistical Methods in Medical Research, vol. 11, no. 6, pp. 455–468, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Claxton, M. Sculpher, C. McCabe et al., “Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra,” Health Economics, vol. 14, no. 4, pp. 339–347, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. D. Lardinois, W. Weder, T. F. Hany et al., “Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography,” The New England Journal of Medicine, vol. 348, no. 25, pp. 2500–2507, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. R. J. Cerfolio, B. Ojha, A. S. Bryant, V. Raghuveer, J. M. Mountz, and A. A. Bartolucci, “The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer,” Annals of Thoracic Surgery, vol. 78, no. 3, pp. 1017–1023, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. B. S. Halpern, C. Schiepers, W. A. Weber et al., “Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion,” Chest, vol. 128, no. 4, pp. 2289–2297, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. S. L. Aquino, J. C. Asmuth, N. M. Alpert, E. F. Halpern, and A. J. Fischman, “Improved radiologic staging of lung cancer with 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography and computed tomography registration,” Journal of Computer Assisted Tomography, vol. 27, no. 4, pp. 479–484, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. A. C. Pfannenberg, P. Aschoff, K. Brechtel et al., “Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 1, pp. 36–44, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. V. H. Gerbaudo and B. Julius, “Anatomo-metabolic characteristics of atelectasis in F-18 FDG-PET/CT imaging,” European Journal of Radiology, vol. 64, no. 3, pp. 401–405, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. B. A. Dwamena, S. S. Sonnad, J. O. Angobaldo, and R. L. Wahl, “Metastases from non-small cell lung cancer: mediastinal staging in the 1990s—meta-analytic comparison of PET and CT,” Radiology, vol. 213, no. 2, pp. 530–536, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. O. Birim, A. P. Kappetein, T. Stijnen, and A. J. Bogers, “Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer,” Annals of Thoracic Surgery, vol. 79, no. 1, pp. 375–382, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Al-Sarraf, K. Gately, J. Lucey, L. Wilson, E. McGovern, and V. Young, “Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1145 lymph nodes,” Lung Cancer, vol. 60, no. 1, pp. 62–68, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. R. M. Pieterman, J. W. G. van Putten, J. J. Meuzelaar et al., “Preoperative staging of non-small-cell lung cancer with positron-emission tomography,” The New England Journal of Medicine, vol. 343, no. 4, pp. 254–261, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. W. Yang, Z. Fu, J. Yu et al., “Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer,” Lung Cancer, vol. 61, no. 1, pp. 35–43, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. K. Kim, K. S. Lee, B. T. Kim et al., “Mediastinal nodal staging of nonsmall cell lung cancer using integrated 18F-FDG PET/CT in a tuberculosis-endemic country: diagnostic efficacy in 674 patients,” Cancer, vol. 109, no. 6, pp. 1068–1077, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. F. C. Detterbeck, M. A. Jantz, M. Wallace, J. Vansteenkiste, and G. A. Silvestri, “Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition),” Chest, vol. 132, supplement 3, pp. 202S–220S, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. L. E. Quint, S. Tummala, L. J. Brisson et al., “Distribution of distant metastases from newly diagnosed non-small cell lung cancer,” The Annals of Thoracic Surgery, vol. 62, no. 1, pp. 246–250, 1996. View at Publisher · View at Google Scholar · View at Scopus
  36. H. van Tinteren, O. S. Hoekstra, E. F. Smit et al., “Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial,” The Lancet, vol. 359, no. 9315, pp. 1388–1392, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. R. J. Cerfolio, A. S. Bryant, M. A. Eloubeidi et al., “The true false negative rates of esophageal and endobronchial ultrasound in the staging of mediastinal lymph nodes in patients with non-small cell lung cancer,” Annals of Thoracic Surgery, vol. 90, no. 2, pp. 427–434, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. V. Ortún, “30.000 euros por AVAC,” Economía y Salud, vol. 49, pp. 1–2, 2004. View at Google Scholar